原发与复发性肝细胞癌的基因组与表观基因组特征
研究对113例接受部分肝切除术的原发或复发性肝细胞癌患者的356份肿瘤标本进行全基因组、全外显子或靶向捕获测序,并对95份标本进行DNA甲基化分析。研究发现52%的复发性肝细胞癌源自初始肿瘤的克隆谱系,肝硬化组织存在场效应,JAK-STAT信号激活与肿瘤进展相关,突变型TP53通过上调染色质调节因子MLL1/MLL2促进细胞增殖,MLL复合物抑制剂可特异性抑制表达TP53R249S的肝癌细胞增殖。
要点
- 52%的复发性肝细胞癌源自初始肿瘤的克隆谱系。
- 肝硬化肝组织DNA甲基化场效应可能预测肿瘤发生风险。
- MLL复合物抑制剂可抑制表达TP53R249S的肝癌细胞增殖。
核心结论
- 复发性肝细胞癌中52%源自初始肿瘤的克隆谱系,基因组与表观基因组特征存在交互与共依赖。
- 肝硬化或纤维化肝组织的DNA甲基化模式可能用于识别肝细胞癌发生风险人群。
- 突变型TP53上调染色质调节因子MLL1和MLL2,MLL复合物拮抗剂可抑制表达TP53R249S的肝癌细胞增殖。
研究设计与样本
- 收集113例在香港2家医院接受部分肝切除术的原发或复发性肝细胞癌患者的肿瘤及配対非肿瘤肝标本。
- 对356份肝细胞癌标本进行全基因组、全外显子或靶向捕获测序分析,涵盖多肿瘤区域及配对的初始与复发肿瘤。
- 对95份标本进行平行DNA甲基化谱分析,并分析含肝硬化或纤维化区域非肿瘤组织的基因组与表观基因组。
- 构建内源性表达突变型TP53(R249S)或过表达突变型STAT3(D170Y、K348E、Y640F)或JAK1(S703I、L910P)的肝癌细胞系,测试药物降低活性的能力。
主要发现
- 系统发育和系统表观遗传学分析显示肝细胞癌的基因组与表观基因组特征之间存在交互与共依赖。
- 甲基化分析显示肝硬化肝组织存在场效应,使其易发生肿瘤。
- 52%的复发性肝细胞癌源自初始肿瘤的克隆谱系,据此构建了与肿瘤复发相关遗传变异的时间图谱。
- JAK-STAT信号激活是肝细胞癌进展的特征,相关突变与药物敏感性反应相关。
- TP53功能获得性突变合并17p染色体缺失可能为肝癌细胞提供复制优势;TP53R249S与编码染色质调节因子MLL1和MLL2的基因相互作用,MLL1和MLL2被验证为TP53R249S的直接靶标。
临床怎么用
- 对肝硬化或纤维化肝组织进行DNA甲基化谱分析可能有助于识别肝细胞癌发生高风险个体。
- 复发性肝细胞癌的克隆起源分析可帮助构建遗传变异时间图谱,指导复发监测与干预策略。
- 对于携带TP53R249S突变的肝细胞癌,MLL复合物拮抗剂在纳摩尔浓度下可特异性抑制癌细胞增殖,提示潜在靶向治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Intratumor heterogeneity and divergent clonal lineages within and among primary and recurrent hepatocellular carcinomas (HCCs) produce challenges to patient management. We investigated genetic and epigenetic variations within liver tumors, among hepatic lesions, and between primary and relapsing tumors. METHODS: Tumor and matched nontumor liver specimens were collected from 113 patients who underwent partial hepatectomy for primary or recurrent HCC at 2 hospitals in Hong Kong. We performed whole-genome, whole-exome, or targeted capture sequencing analyses of 356 HCC specimens collected from multiple tumor regions and matched initial and recurrent tumors. We performed parallel DNA methylation profiling analyses of 95 specimens. Genomes and epigenomes of nontumor tissues that contained areas of cirrhosis or fibrosis were analyzed. We developed liver cancer cell lines that endogenously expressed a mutant form of TP53 (R249S) or overexpressed mutant forms of STAT3 (D170Y, K348E, and Y640F) or JAK1 (S703I and L910P) and tested the abilities of pharmacologic agents to reduce activity. Cells were analyzed by immunoblotting and chromatin immunoprecipitation with quantitative polymerase chain reaction. RESULTS: We determined the monoclonal origins of individual tumors using a single-sample collection approach that captured more than 90% of mutations that are detected in all regions of tumors. Phylogenetic and phyloepigenetic analyses showed interactions and codependence between the genomic and epigenomic features of HCCs. Methylation analysis showed a field effect in cirrhotic liver tissues that predisposes them to tumor development. Comparisons of genetic features showed that 52% of recurrent HCCs derive from the clonal lineage of the initial tumor. The clonal origin of recurrent HCCs allowed construction of a temporal map of genetic alterations that were associated with tumor recurrence. Activation of JAK signaling to STAT was a characteristic of HCC progression via mutations that are associated with response to drug sensitivity. The combination of a mutation that increases the function of TP53 and the 17p chromosome deletion might provide liver cancer cells with a replicative advantage. Chromatin immunoprecipitation analysis of TP53 with the R249S substitution showed its interaction with genes that encode chromatin regulators (MLL1 and MLL2). We validated MLL1 and MLL2 as direct targets of TP53R249S and affirmed their association in the cancer genome atlas data set. The MLL-complex antagonists MI-2-2 (inhibitor of protein interaction) and OICR-9492 (inhibitor of activity) specifically inhibited proliferation of HCC cells that express TP53R249S at nanomolar concentrations. CONCLUSIONS: We performed a systematic evaluation of intra- and intertumor genetic heterogeneity in HCC samples and identified genetic and epigenetic changes that are associated with tumor progression and recurrence. We identified chromatin regulators that are up-regulated by mutant TP53 in HCC cells and inhibitors that reduce proliferation of these cells. DNA methylation patterns in cirrhotic or fibrotic liver tissues might be used to identify those at risk of HCC development.
引用
- Ding X, He M, Chan AWH, et al. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. Gastroenterology. 2020. PMID: 32428506. doi:10.1053/j.gastro.2019.09.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。